Medication Use Before and During Pregnancy in Japan: the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2024 Apr 17

PMID 38630193

Authors

Aoi Noda

Taku Obara

Matsuyuki Shirota

Fumihiko Ueno

Fumiko Matsuzaki

Rieko Hatanaka

Ryo Obara

Kei Morishita

Genki Shinoda

Masatsugu Orui

Keiko Murakami

Mami Ishikuro

Shinichi Kuriyama

Affiliations

Soon will be listed here.

Abstract

Purpose: To elucidate the status of medication use among pregnant women in Japan, by means of a multigenerational genome and birth cohort study: the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study).

Methods: Questionnaires were distributed to pregnant women participating in the TMM BirThree Cohort Study (from July 2013 to March 2017) around 12 weeks (early pregnancy) and 26 weeks (middle pregnancy). We analysed medication use over three periods: (1) 12 months prior to pregnancy diagnosis, (2) the period between pregnancy diagnosis and around week 12 of pregnancy, and (3) post around week 12 of pregnancy.

Results: In total, 19,297 women were included in the analysis. The proportion of pregnant women using medications was 49.0% prior to pregnancy diagnosis, 52.1% from diagnosis to week 12, and 58.4% post week 12 of pregnancy. The most frequently prescribed medications were loxoprofen sodium hydrate (5.5%) prior to pregnancy diagnosis, magnesium oxide (5.9%) from diagnosis to week 12, and ritodrine hydrochloride (10.5%) post week 12 of pregnancy. The number of women who used suspected teratogenic medications during early pregnancy was 96 prior to pregnancy diagnosis, 48 from diagnosis to week 12, and 54 post week 12 of pregnancy.

Conclusion: We found that ~ 50% of the pregnant women used medications before and during pregnancy and some took potential teratogenic medications during pregnancy. In birth genomic cohort study, it is expected that investigations into the safety and effectiveness of medications used during pregnancy will advance.

References

Mitchell A, Gilboa S, Werler M, Kelley K, Louik C, Hernandez-Diaz S . Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011; 205(1):51.e1-8. PMC: 3793635. DOI: 10.1016/j.ajog.2011.02.029. View

Ishikuro M, Obara T, Osanai T, Yamanaka C, Sato Y, Mizuno S . Strategic Methods for Recruiting Grandparents: The Tohoku Medical Megabank Birth and Three-Generation Cohort Study. Tohoku J Exp Med. 2018; 246(2):97-105. DOI: 10.1620/tjem.246.97. View

Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M . KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2009; 38(Database issue):D355-60. PMC: 2808910. DOI: 10.1093/nar/gkp896. View

Larcin L, Lona M, Karakaya G, Van Espen A, Damase-Michel C, Kirakoya-Samadoulougou F . Using administrative healthcare database records to study trends in prescribed medication dispensed during pregnancy in Belgium from 2003 to 2017. Pharmacoepidemiol Drug Saf. 2021; 30(9):1224-1232. DOI: 10.1002/pds.5299. View

Hall H, Griffiths D, McKenna L . The use of complementary and alternative medicine by pregnant women: a literature review. Midwifery. 2011; 27(6):817-24. DOI: 10.1016/j.midw.2010.08.007. View

Traerup Andersen J, Andersen N, Horwitz H, Poulsen H, Jimenez-Solem E . Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol. 2014; 124(4):655-661. DOI: 10.1097/AOG.0000000000000447. View

de Jong-van den Berg L, Waardenburg C, Haaijer-Ruskamp F, Dukes M, Wesseling H . Drug use in pregnancy: a comparative appraisal of data collecting methods. Eur J Clin Pharmacol. 1993; 45(1):9-14. DOI: 10.1007/BF00315343. View

Thygesen L, Ersboll A . Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health. 2011; 39(7 Suppl):8-10. DOI: 10.1177/1403494811409654. View

Berard A, Abbas-Chorfa F, Kassai B, Vial T, Nguyen K, Sheehy O . The French Pregnancy Cohort: Medication use during pregnancy in the French population. PLoS One. 2019; 14(7):e0219095. PMC: 6636733. DOI: 10.1371/journal.pone.0219095. View

10.

Huybrechts K, Kulldorff M, Hernandez-Diaz S, Bateman B, Zhu Y, Mogun H . Active Surveillance of the Safety of Medications Used During Pregnancy. Am J Epidemiol. 2021; 190(6):1159-1168. DOI: 10.1093/aje/kwaa288. View

11.

Nishigori H, Obara T, Nishigori T, Metoki H, Ishikuro M, Mizuno S . Drug Use before and during Pregnancy in Japan: The Japan Environment and Children's Study. Pharmacy (Basel). 2017; 5(2). PMC: 5597146. DOI: 10.3390/pharmacy5020021. View

12.

Daw J, Hanley G, Greyson D, Morgan S . Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011; 20(9):895-902. PMC: 3423446. DOI: 10.1002/pds.2184. View

13.

Campbell E, Kennedy F, Russell A, Smithson W, Parsons L, Morrison P . Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85(9):1029-34. DOI: 10.1136/jnnp-2013-306318. View

14.

Hurault-Delarue C, Morris J, Charlton R, Gini R, Loane M, Pierini A . Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries. Pharmacoepidemiol Drug Saf. 2019; 28(11):1510-1518. DOI: 10.1002/pds.4897. View

15.

Ishikawa T, Obara T, Jin K, Nishigori H, Miyakoda K, Suzuka M . Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from a health administrative database. Pharmacoepidemiol Drug Saf. 2019; 28(6):804-811. DOI: 10.1002/pds.4749. View

16.

Palmsten K, Simard J, Chambers C, Arkema E . Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatology (Oxford). 2016; 56(4):561-569. PMC: 5850850. DOI: 10.1093/rheumatology/kew448. View

17.

Fukai K, Nagata T, Mori K, Ohtani M, Fujimoto K, Nagata M . Validation of self-reported medication use for hypertension, diabetes, and dyslipidemia among employees of large-sized companies in Japan. J Occup Health. 2020; 62(1):e12138. PMC: 7382304. DOI: 10.1002/1348-9585.12138. View

18.

Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N . The Tohoku Medical Megabank Project: Design and Mission. J Epidemiol. 2016; 26(9):493-511. PMC: 5008970. DOI: 10.2188/jea.JE20150268. View

19.

Roza S, van Batenburg-Eddes T, Steegers E, Jaddoe V, Mackenbach J, Hofman A . Maternal folic acid supplement use in early pregnancy and child behavioural problems: The Generation R Study. Br J Nutr. 2009; 103(3):445-52. DOI: 10.1017/S0007114509991954. View

20.

Ahmed M, Hwang J, Choi S, Han D . Safety classification of herbal medicines used among pregnant women in Asian countries: a systematic review. BMC Complement Altern Med. 2017; 17(1):489. PMC: 5686907. DOI: 10.1186/s12906-017-1995-6. View